Our Team
Members of our Senior Executive Team have working relationships spanning over 20 years and a shared ambition to make TrophiCells the leading clinical choice in cell therapeutics.
PROFESSOR ANTHONY HOLLANDER
CSO and founding academic
TrophiCell is founded on a broad technology and IP platform generated by Professor Anthony Hollander, Pro-Vice-Chancellor for Research and Impact and Professor of Stem Cell Biology, University of Liverpool. Anthony is a serial entrepreneur whose research career has focused on the development of stem cell therapies for treating diseases of cartilage and his previous spin-out company, Azellon Ltd, has developed a stem cell treatment for torn knee cartilage. He is the incoming chair of the Russell Group Universities’ Research Pro-Vice-Chancellors and a full member of the California Institute for Regenerative Medicine Grant Working Group. He is a former President of the International Cartilage Repair Society and Chair of Utrecht University’s International Scientific and Societal Advisory Board for Life Sciences. He has been involved in several large, strategic European collaborative programmes, for tissue engineering, including Scafcart (Framework 5), STEPS (Framework 6) and BIO-COMET (Framework 7).
DR KAREN SULLIVAN
CEO
Dr Karen Sullivan is a scientist and lawyer with over 20 years’ experience in technology commercialisation in the public and private sector. Whilst Director of Intellectual Asset Management and Commercialisation at ITI Life Sciences, a £150m public sector technology investment fund, she led a major investment in stem cell technology and later led on the development of a national stem cell strategy for Scotland for Scottish Enterprise. Karen has closed well over 100 technology transactions spanning all technology sectors and covering assignment, licences, options, Joint ventures and spin outs, and has served on national working groups on best practice in commercialisation of research. She brings many years of senior management experience and commercial acumen to the leadership of TrophiCell.
HELEN DELAHAYE
Operations and Programme Management
Helen Delahaye has had various Director, Programme and Project Leadership positions, and formerly worked with both CRO and Pharma companies including; ProStrakan (including management of a research team at KPU, Japan), Quintiles and Pfizer (France & UK). Since 2002, Helen has led a Programme Management Company and notably worked with Azellon, a spin-out Company from the University of Bristol, where she managed all aspects of a Phase 1/2a clinical trial with an autologous cell therapy. She then supported the team to win an Innovate UK award for the successful development of an allogeneic version of the product ready for clinical trials. Helen maintains a strong network of contacts and knowledge of the sector and is Vice Chair of the BIA’s Cell and Gene Advisory Committee.
DR ALISON WILSON
Regulatory Advisor
Dr Alison Wilson is an independent regulatory consultant specialising in advanced therapy medicinal products. Previously regulatory affairs manager for a global medical technology company, she has over 30 years’ experience of regulatory affairs in medicinal products, cell-based therapies and medical devices. She is a member of BSI Technical Panel BTS/1 – Biotechnologies, and a member of both the Scientific Advisory Board and Safety and Immunology Panel for the UK Regenerative Medicine Platform (Acellular Scaffolds Hub).